BMA Fundamental Analysis - BYGGMA ASA

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to BMA. BMA was compared to 23 industry peers in the Building Products industry. BMA may be in some trouble as it scores bad on both profitability and health. BMA does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year BMA has reported negative net income.
BMA had a positive operating cash flow in the past year.
BMA had positive earnings in 4 of the past 5 years.
In the past 5 years BMA always reported a positive cash flow from operatings.

1.2 Ratios

BMA has a Return On Assets of -3.03%. This is amonst the worse of the industry: BMA underperforms 85.19% of its industry peers.
The Return On Equity of BMA (-9.11%) is worse than 85.19% of its industry peers.
The Return On Invested Capital of BMA (2.29%) is worse than 77.78% of its industry peers.

		Industry Rank	Sector Rank
ROA	-3.03%
ROE	-9.11%
ROIC	2.29%

ROA(3y)2.06%

ROA(5y)4.25%

ROE(3y)5.65%

ROE(5y)11.19%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a Operating Margin value of 2.99%, BMA is not doing good in the industry: 77.78% of the companies in the same industry are doing better.
BMA has a Gross Margin of 49.71%. This is in the better half of the industry: BMA outperforms 70.37% of its industry peers.
BMA's Gross Margin has been stable in the last couple of years.

		Industry Rank	Sector Rank
OM	2.99%
PM (TTM)	N/A
GM	49.71%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.39%

GM growth 5Y-0.63%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BMA is destroying value.
BMA has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, BMA has more shares outstanding
Compared to 1 year ago, BMA has a worse debt to assets ratio.

2.2 Solvency

BMA has an Altman-Z score of 1.42. This is a bad value and indicates that BMA is not financially healthy and even has some risk of bankruptcy.
BMA's Altman-Z score of 1.42 is on the low side compared to the rest of the industry. BMA is outperformed by 81.48% of its industry peers.
A Debt/Equity ratio of 1.14 is on the high side and indicates that BMA has dependencies on debt financing.
With a Debt to Equity ratio value of 1.14, BMA is not doing good in the industry: 77.78% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	1.14
Debt/FCF	N/A
Altman-Z	1.42

ROIC/WACC0.25

WACC9.06%

2.3 Liquidity

BMA has a Current Ratio of 0.78. This is a bad value and indicates that BMA is not financially healthy enough and could expect problems in meeting its short term obligations.
BMA has a worse Current ratio (0.78) than 88.89% of its industry peers.
BMA has a Quick Ratio of 0.78. This is a bad value and indicates that BMA is not financially healthy enough and could expect problems in meeting its short term obligations.
BMA has a worse Quick ratio (0.41) than 85.19% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.78
Quick Ratio	0.41

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

BMA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -41.76%.
BMA shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.19%.
The Revenue has been growing slightly by 3.98% on average over the past years.

EPS 1Y (TTM)-41.76%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-60.49%

Revenue 1Y (TTM)8.19%

Revenue growth 3Y-2.58%

Revenue growth 5Y3.98%

Sales Q2Q%8.04%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BMA. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

BMA's Enterprise Value to EBITDA ratio is in line with the industry average.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	13.2

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BMA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BYGGMA ASA

OSL:BMA (11/20/2025, 7:00:00 PM)

13.8

0 (0%)

Chartmill FA Rating

GICS SectorIndustrials

GICS IndustryGroupCapital Goods

GICS IndustryBuilding Products

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners2.71%

Ins Owner ChangeN/A

Market Cap963.65M

Revenue(TTM)2.31B

Net Income(TTM)-94.28M

AnalystsN/A

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly Dividend0

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.42
P/FCF	N/A
P/OCF	37.89
P/B	0.93
P/tB	0.95
EV/EBITDA	13.2

EPS(TTM)-1.33

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-0.54

FCFYN/A

OCF(TTM)0.36

OCFY2.64%

SpS33.02

BVpS14.81

TBVpS14.58

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-3.03%
ROE	-9.11%
ROCE	3.47%
ROIC	2.29%
ROICexc	2.32%
ROICexgc	2.33%
OM	2.99%
PM (TTM)	N/A
GM	49.71%
FCFM	N/A

ROA(3y)2.06%

ROA(5y)4.25%

ROE(3y)5.65%

ROE(5y)11.19%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.39%

GM growth 5Y-0.63%

F-Score5

Asset Turnover0.74

Health

		Industry Rank	Sector Rank
Debt/Equity	1.14
Debt/FCF	N/A
Debt/EBITDA	7.54
Cap/Depr	71.91%
Cap/Sales	2.74%
Interest Coverage	0.7
Cash Conversion	16.21%
Profit Quality	N/A
Current Ratio	0.78
Quick Ratio	0.41
Altman-Z	1.42

F-Score5

WACC9.06%

ROIC/WACC0.25

Cap/Depr(3y)82.97%

Cap/Depr(5y)85.75%

Cap/Sales(3y)3.16%

Cap/Sales(5y)3.26%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-41.76%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-60.49%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)8.19%

Revenue growth 3Y-2.58%

Revenue growth 5Y3.98%

Sales Q2Q%8.04%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y138.78%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-130.75%

FCF growth 3Y-35.16%

FCF growth 5YN/A

OCF growth 1Y-89.51%

OCF growth 3Y-28.69%

OCF growth 5Y-8.56%

BYGGMA ASA / BMA.OL FAQ

What is the ChartMill fundamental rating of BYGGMA ASA (BMA.OL) stock?

ChartMill assigns a fundamental rating of 1 / 10 to BMA.OL.

What is the valuation status for BMA stock?

ChartMill assigns a valuation rating of 0 / 10 to BYGGMA ASA (BMA.OL). This can be considered as Overvalued.

Can you provide the profitability details for BYGGMA ASA?

BYGGMA ASA (BMA.OL) has a profitability rating of 2 / 10.

BYGGMA ASA (BMA.OL) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

BYGGMA ASA / BMA.OL FAQ

What is the ChartMill fundamental rating of BYGGMA ASA (BMA.OL) stock?

What is the valuation status for BMA stock?

Can you provide the profitability details for BYGGMA ASA?